English

STEMLINE THERAPEUTICS INC

EDGAR

Quarterly report (10-Q) · filed 2020-05-11

44 filing records in this dataset, filed from 2012-04-02 to 2020-05-11. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

8.87 million Unit12

2020 Q1 · Unit12

Exact inputs and evidence

Revenue: 8872634 Unit12 Source

Operating margin

-246.3%

2020 Q1 · %

Exact inputs and evidence

Operating Income: -21853046 Unit12 Source
Revenue: 8872634 Unit12 Source

Operating cash flow

-13.8 million Unit12

2020 Q1 · Unit12

Exact inputs and evidence

Operating Cash Flow: -13773474 Unit12 Source

Free cash flow

-13.8 million Unit12

2020 Q1 · Unit12

Exact inputs and evidence

Operating Cash Flow: -13773474 Unit12 Source
Capital Expenditure: 14523 Unit12 Source

Cash and cash equivalents: 29.2 million Unit12 2020-03-31 Source
Exact value

29230953 Unit12
Long-term debt including current maturities: Not available
Shares outstanding: 52.5 million Unit1 2020-03-31 Source
Exact value

52504598 Unit1

Reported share-count change

20.49% · 8.93 million Unit1

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

43576081 Unit1 · 2019-03-31· Source
52504598 Unit1 · 2020-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-70.7 million Unit12

2019-04-01 – 2020-03-31

Exact inputs and evidence

Net income: -16841422 Unit12 · 2019-04-01 – 2019-06-30 Source
Net income: -14888512 Unit12 · 2019-07-01 – 2019-09-30 Source
Net income: -17680025 Unit12 · 2019-10-01 – 2019-12-31 Source
Net income: -21293505 Unit12 · 2020-01-01 – 2020-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2020-05-11.

Financial data available through: 2018-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2018-12-31
Operating income: 7 of 11 periods available· newest 2018-12-31
Net income: 4 of 11 periods available· newest 2018-12-31
Operating cash flow: 7 of 11 periods available· newest 2018-12-31
capital expenditure: No compatible figures in this window
Total assets: 3 of 11 periods available· newest 2018-12-31
Total liabilities: 3 of 11 periods available· newest 2018-12-31
Current assets: 3 of 11 periods available· newest 2018-12-31
Current liabilities: 3 of 11 periods available· newest 2018-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2018-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2018-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-44.3%

Prior period

Unit12 898,199

2017-01-01 – 2017-12-31
Current period

Unit12 500,000

2018-01-01 – 2018-12-31

Exact inputs and evidence

500000 − 898199 = -398199 Unit12

898199 Unit12 · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
500000 Unit12 · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · STEMLINE THERAPEUTICS INC · 2018-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Year-over-year change in Revenue: -398199 Unit12 Concept: fundies:Revenue Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 500000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465919015293/stml-20181231.xml#1665899 Filing: 000110465919015293 Input fundies:Revenue: 898199 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465919015293/stml-20181231.xml#1665150 Filing: 000110465919015293
The citation records this snapshot. The page link may show a newer release later.
Net income
−Unit12 17.2 million

Prior period

−Unit12 67.83 million

2017-01-01 – 2017-12-31
Current period

−Unit12 85.02 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

-85024365 − -67828394 = -17195971 Unit12

-67828394 Unit12 · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
-85024365 Unit12 · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · STEMLINE THERAPEUTICS INC · 2018-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Year-over-year change in Net income: -17195971 Unit12 Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -85024365 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465920034154/stml-20191231.xml#1545170 Filing: 000110465920034154 Input fundies:NetIncome: -67828394 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465920034154/stml-20191231.xml#1544298 Filing: 000110465920034154
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−Unit12 22.56 million

Prior period

−Unit12 49.62 million

2017-01-01 – 2017-12-31
Current period

−Unit12 72.18 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

-72181918 − -49618794 = -22563124 Unit12

-49618794 Unit12 · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
-72181918 Unit12 · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · STEMLINE THERAPEUTICS INC · 2018-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Year-over-year change in Operating cash flow: -22563124 Unit12 Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -72181918 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465920034154/stml-20191231.xml#1543376 Filing: 000110465920034154 Input fundies:OperatingCashFlow: -49618794 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465920034154/stml-20191231.xml#1543184 Filing: 000110465920034154
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2018 2018-01-01 – 2018-12-31

Revenue Unit12 500,000 100% of revenue
Operating costs Derived Unit12 86.79 million 17,357% of revenue
Operating income −Unit12 86.29 million −17,257% of revenue
Tax, interest and other Derived −Unit12 1.26 million −252% of revenue
Net income −Unit12 85.02 million −17,005% of revenue

Cash

Operating cash flow −Unit12 72.18 million −14,436% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 3,834% of revenue.
2017 Operating loss: operating costs were 7,733% of revenue.
2018 Operating loss: operating costs were 17,357% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	1041354	39926811 Derived	-38885457	-582452 Derived	-38303005	Unavailable	Source 2016-01-01 – 2016-12-31: 1041354 Unit12 Inspect Revenue Open source 2016-01-01 – 2016-12-31: -38885457 Unit12 Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -38303005 Unit12 Inspect Net Income Open source 2016-01-01 – 2016-12-31: -30092774 Unit12 Inspect Operating Cash Flow Open source
2017 2017-01-01 – 2017-12-31	898199	69456593 Derived	-68558394	-730000 Derived	-67828394	Unavailable	Source 2017-01-01 – 2017-12-31: 898199 Unit12 Inspect Revenue Open source 2017-01-01 – 2017-12-31: -68558394 Unit12 Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -67828394 Unit12 Inspect Net Income Open source 2017-01-01 – 2017-12-31: -49618794 Unit12 Inspect Operating Cash Flow Open source
2018 2018-01-01 – 2018-12-31	500000	86786686 Derived	-86286686	-1262321 Derived	-85024365	Unavailable	Source 2018-01-01 – 2018-12-31: 500000 Unit12 Inspect Revenue Open source 2018-01-01 – 2018-12-31: -86286686 Unit12 Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -85024365 Unit12 Inspect Net Income Open source 2018-01-01 – 2018-12-31: -72181918 Unit12 Inspect Operating Cash Flow Open source

Amounts are exact, in Unit12.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit12 500K 2018

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit12)	Source evidence
20162016-12-31	Revenue	1041354	Revenue: 1041354 Open source
20172017-12-31	Revenue	898199	Revenue: 898199 Open source
20182018-12-31	Revenue	500000	Revenue: 500000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-44.3% 2018

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 1041354 Open source
20172017-12-31	Year over year	-13.7%	Revenue: 898199 Open source Revenue: 1041354 Open source
20182018-12-31	Year over year	-44.3%	Revenue: 500000 Open source Revenue: 898199 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -17,257.3% 2018

Net margin -17,004.9% 2018

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-3,734.1%	Operating Income: -38885457 Open source Revenue: 1041354 Open source
20172017-12-31	Operating margin	-7,632.9%	Operating Income: -68558394 Open source Revenue: 898199 Open source
20182018-12-31	Operating margin	-17,257.3%	Operating Income: -86286686 Open source Revenue: 500000 Open source
20162016-12-31	Net margin	-3,678.2%	Net Income: -38303005 Open source Revenue: 1041354 Open source
20172017-12-31	Net margin	-7,551.6%	Net Income: -67828394 Open source Revenue: 898199 Open source
20182018-12-31	Net margin	-17,004.9%	Net Income: -85024365 Open source Revenue: 500000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 1041354 Open source Operating Cash Flow: -30092774 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 898199 Open source Operating Cash Flow: -49618794 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 500000 Open source Operating Cash Flow: -72181918 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit12 -72.2M 2018

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit12)	Source evidence
20162016-12-31	Operating cash flow	-30092774	Operating Cash Flow: -30092774 Open source
20172017-12-31	Operating cash flow	-49618794	Operating Cash Flow: -49618794 Open source
20182018-12-31	Operating cash flow	-72181918	Operating Cash Flow: -72181918 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit12)	Source evidence
20162016-12-31	Free cash flow	Unavailable	Operating Cash Flow: -30092774 Open source
20172017-12-31	Free cash flow	Unavailable	Operating Cash Flow: -49618794 Open source
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -72181918 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

33.5% 2018

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	15.3%	Total Liabilities: 10396013 Open source Total Assets: 68119098 Open source
20172017-12-31	Liabilities / assets	29.8%	Total Liabilities: 19935739 Open source Total Assets: 67006168 Open source
20182018-12-31	Liabilities / assets	33.5%	Total Liabilities: 21291515 Open source Total Assets: 63493570 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.97× 2018

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	4.6×	Current Assets: 47169711 Open source Current Liabilities: 10253813 Open source
20172017-12-31	Current assets / current liabilities	2.63×	Current Assets: 52188777 Open source Current Liabilities: 19838913 Open source
20182018-12-31	Current assets / current liabilities	2.97×	Current Assets: 63058852 Open source Current Liabilities: 21218924 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	Unavailable Not reported for this period.	−Unit12 4.13 million Exact value Exact value: -4126548 Unit12 2012-01-01 – 2012-12-31: -4126548 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · STEMLINE THERAPEUTICS INC · 2012-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Operating Cash Flow: -4126548 Unit12 Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -4126548 Unit12 (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465915020076/stml-20141231.xml#888821 Filing: 000110465915020076 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2013 2013-01-01 – 2013-12-31	Unavailable Not reported for this period.	−Unit12 16.12 million Exact value Exact value: -16118487 Unit12 2013-01-01 – 2013-12-31: -16118487 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · STEMLINE THERAPEUTICS INC · 2013-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Operating Cash Flow: -16118487 Unit12 Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -16118487 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465916104922/stml-20151231.xml#1099711 Filing: 000110465916104922 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2014 2014-01-01 – 2014-12-31	Unavailable Not reported for this period.	−Unit12 25.71 million Exact value Exact value: -25713445 Unit12 2014-01-01 – 2014-12-31: -25713445 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · STEMLINE THERAPEUTICS INC · 2014-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Operating Cash Flow: -25713445 Unit12 Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -25713445 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465917017199/stml-20161231.xml#1136623 Filing: 000110465917017199 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2015 2015-01-01 – 2015-12-31	−Unit12 37.24 million Exact value Exact value: -37243861 Unit12 2015-01-01 – 2015-12-31: -37243861 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · STEMLINE THERAPEUTICS INC · 2015-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Net Income: -37243861 Unit12 Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit12&dimensions= Input fundies:NetIncome: -37243861 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465918018361/stml-20171231.xml#1188663 Filing: 000110465918018361 The citation records this snapshot. The page link may show a newer release later.	−Unit12 25.59 million Exact value Exact value: -25589442 Unit12 2015-01-01 – 2015-12-31: -25589442 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · STEMLINE THERAPEUTICS INC · 2015-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Operating Cash Flow: -25589442 Unit12 Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -25589442 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465918018361/stml-20171231.xml#1187951 Filing: 000110465918018361 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2016-01-01 – 2016-12-31	−Unit12 38.3 million Exact value Exact value: -38303005 Unit12 2016-01-01 – 2016-12-31: -38303005 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · STEMLINE THERAPEUTICS INC · 2016-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Net Income: -38303005 Unit12 Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit12&dimensions= Input fundies:NetIncome: -38303005 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465919015293/stml-20181231.xml#1454110 Filing: 000110465919015293 The citation records this snapshot. The page link may show a newer release later.	−Unit12 30.09 million Exact value Exact value: -30092774 Unit12 2016-01-01 – 2016-12-31: -30092774 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · STEMLINE THERAPEUTICS INC · 2016-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Operating Cash Flow: -30092774 Unit12 Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -30092774 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465919015293/stml-20181231.xml#1452996 Filing: 000110465919015293 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−Unit12 67.83 million Exact value Exact value: -67828394 Unit12 2017-01-01 – 2017-12-31: -67828394 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · STEMLINE THERAPEUTICS INC · 2017-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Net Income: -67828394 Unit12 Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit12&dimensions= Input fundies:NetIncome: -67828394 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465920034154/stml-20191231.xml#1544298 Filing: 000110465920034154 The citation records this snapshot. The page link may show a newer release later.	−Unit12 49.62 million Exact value Exact value: -49618794 Unit12 2017-01-01 – 2017-12-31: -49618794 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · STEMLINE THERAPEUTICS INC · 2017-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Operating Cash Flow: -49618794 Unit12 Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -49618794 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465920034154/stml-20191231.xml#1543184 Filing: 000110465920034154 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−Unit12 85.02 million Exact value Exact value: -85024365 Unit12 2018-01-01 – 2018-12-31: -85024365 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · STEMLINE THERAPEUTICS INC · 2018-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Net Income: -85024365 Unit12 Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=Unit12&dimensions= Input fundies:NetIncome: -85024365 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465920034154/stml-20191231.xml#1545170 Filing: 000110465920034154 The citation records this snapshot. The page link may show a newer release later.	−Unit12 72.18 million Exact value Exact value: -72181918 Unit12 2018-01-01 – 2018-12-31: -72181918 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · STEMLINE THERAPEUTICS INC · 2018-12-31 STEMLINE THERAPEUTICS INC (edgar:1264587) Operating Cash Flow: -72181918 Unit12 Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1264587/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -72181918 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1264587/000110465920034154/stml-20191231.xml#1543376 Filing: 000110465920034154 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

44 filings · 1,778 latest values · 1,778 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001264587, 1264587, edgar:1264587

Also known as STEMLINE THERAPEUTICS INC

STEMLINE THERAPEUTICS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2018 2018-01-01 – 2018-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation